Arthur S. Kirsch
CIK: 0001290976
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (11 total)
- Jul 7, 2026EVMN
Evommune, Inc.
Purchase(P)Indirect10K shares at avg. $13.30$133K - Jun 18, 2026AVIR
Atea Pharmaceuticals, Inc.
Award(A)DirectStock Option (Right to Buy)
37.7K shares- - Jun 18, 2026AVIR
Atea Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
26.7K shares- - Jun 16, 2026LQDA
Liquidia Corp
Award(A)Direct5.9K shares- - Jun 3, 2026LQDA
Liquidia Corp
Sale(S)Indirect10K shares at avg. $54.80$548K - Jun 2, 2026EVMN
Evommune, Inc.
Award(A)DirectStock Option (Right to buy)
15.7K shares- - Jun 2, 2026LQDA
Liquidia Corp
Sale(S)Indirect5K shares at avg. $56.00$280K - Jun 1, 2026LQDA
Liquidia Corp
Sale(S)Indirect15K shares at avg. $60.22$903K - Nov 5, 2025EVMN
Evommune, Inc.
Award(A)DirectStock Option (Right to Buy)
38K shares- - Jun 17, 2025LQDA
Liquidia Corp
Award(A)Direct18.4K shares- - Feb 20, 2025AVIR
Atea Pharmaceuticals, Inc.
Award(A)DirectStock Option (Right to Buy)
164.8K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 7, 2026 |  EVMN Evommune, Inc. | Purchase(P) | 10,000 | $13.30 | $133,000 | Indirect |
| Jun 18, 2026 |  AVIR Atea Pharmaceuticals, Inc. | Award(A) Stock Option (Right to Buy) | 37,700 | - | - | Direct |
| Jun 18, 2026 | AVIR Atea Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 26,700 | - | - | Direct |
| Jun 16, 2026 |  LQDA Liquidia Corp | Award(A) | 5,882 | - | $0 | Direct |
| Jun 3, 2026 | LQDA Liquidia Corp | Sale(S) | 10,000 | $54.80 | $548,000 | Indirect |
| Jun 2, 2026 | EVMN Evommune, Inc. | Award(A) Stock Option (Right to buy) | 15,673 | - | - | Direct |
| Jun 2, 2026 | LQDA Liquidia Corp | Sale(S) | 5,000 | $56.00 | $280,000 | Indirect |
| Jun 1, 2026 | LQDA Liquidia Corp | Sale(S) | 15,000 | $60.22 | $903,300 | Indirect |
| Nov 5, 2025 | EVMN Evommune, Inc. | Award(A) Stock Option (Right to Buy) | 37,960 | - | - | Direct |
| Jun 17, 2025 | LQDA Liquidia Corp | Award(A) | 18,396 | - | - | Direct |
| Feb 20, 2025 | AVIR Atea Pharmaceuticals, Inc. | Award(A) Stock Option (Right to Buy) | 164,800 | - | - | Direct |
1-11 of 11 transactions
About KIRSCH ARTHUR S
KIRSCH ARTHUR S (SEC CIK 0001290976) files insider reports with the SEC as Director of Evommune, Inc. (EVMN), Director of Atea Pharmaceuticals, Inc. (AVIR) and Director of Liquidia Corp (LQDA).
Signal8 holds 10 ownership filings by KIRSCH ARTHUR S (2 Form 3, 8 Form 4), filed between Feb 24, 2025 and Jul 8, 2026. Those filings report 11 transactions, from Feb 20, 2025 to Jul 7, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on KIRSCH ARTHUR S's filings is in PALO ALTO, CA.
Recent filings by KIRSCH ARTHUR S
- Jul 7, 2026: Open-market purchase of EVMN shares (Form 4, code P).
- Jun 18, 2026: Grants or awards of AVIR derivative securities (2 lines, Form 4, code A).
- Jun 16, 2026: Grant or award of LQDA shares (Form 4, code A).
- Jun 3, 2026: Open-market sale of LQDA shares (Form 4, code S).
- Jun 2, 2026: Grant or award of EVMN derivative securities (Form 4, code A).
Other insiders filing for Evommune, Inc. (EVMN)
- Pena Luis C., President & CEO
- Carver Kyle, Chief Financial Officer
- Drew Janice Suzann, Chief of Dev. Operations
- Patel Jeegar Pravinkumar, Chief Scientific Officer
- MCGRAW BENJAMIN F III, Director
- Cohen David E, Director